FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977690259> ?p ?o ?g. }

• W2977690259 endingPage "4931" @default.
• W2977690259 startingPage "4931" @default.
• W2977690259 abstract "Manipulation of the immune response is a game changer in lung cancer treatment, revolutionizing management. PD1 and CTLA4 are dynamically expressed on different T cell subsets that can either disrupt or sustain tumor growth. Monoclonal antibodies (MoAbs) against PD1/PDL1 and CTLA4 have shown that inhibitory signals can be impaired, blocking T cell activation and function. MoAbs, used as both single-agents or in combination with standard therapy for the treatment of advanced non-small cell lung cancer (NSCLC), have exhibited advantages in terms of overall survival and response rate; nivolumab, pembrolizumab, atezolizumab and more recently, durvalumab, have already been approved for lung cancer treatment and more compounds are in the pipeline. A better understanding of signaling elicited by these antibodies on T cell subsets, as well as identification of biological determinants of sensitivity, resistance and correlates of efficacy, will help to define the mechanisms of antitumor responses. In addition, the relevance of T regulatory cells (Treg) involved in immune responses in cancer is attracting increasing interest. A major challenge for future research is to understand why a durable response to immune checkpoint inhibitors (ICIs) occurs only in subsets of patients and the mechanisms of resistance after an initial response. This review will explore current understanding and future direction of research on ICI treatment in lung cancer and the impact of tumor immune microenvironment n influencing clinical responses." @default.
• W2977690259 created "2019-10-10" @default.
• W2977690259 creator A5003880441 @default.
• W2977690259 creator A5017669867 @default.
• W2977690259 creator A5019347720 @default.
• W2977690259 creator A5028834608 @default.
• W2977690259 creator A5052641781 @default.
• W2977690259 creator A5073420952 @default.
• W2977690259 date "2019-10-05" @default.
• W2977690259 modified "2023-10-14" @default.
• W2977690259 title "Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer" @default.
• W2977690259 cites W1487795229 @default.
• W2977690259 cites W1542616270 @default.
• W2977690259 cites W1661347229 @default.
• W2977690259 cites W1889335134 @default.
• W2977690259 cites W1895620535 @default.
• W2977690259 cites W1988314473 @default.
• W2977690259 cites W2011458181 @default.
• W2977690259 cites W2024384252 @default.
• W2977690259 cites W2046409157 @default.
• W2977690259 cites W2049553585 @default.
• W2977690259 cites W2066002010 @default.
• W2977690259 cites W2076791524 @default.
• W2977690259 cites W2108933323 @default.
• W2977690259 cites W2118471749 @default.
• W2977690259 cites W2120010406 @default.
• W2977690259 cites W2125665528 @default.
• W2977690259 cites W2127700366 @default.
• W2977690259 cites W2144953100 @default.
• W2977690259 cites W2156657486 @default.
• W2977690259 cites W2162466652 @default.
• W2977690259 cites W2163351155 @default.
• W2977690259 cites W2168197710 @default.
• W2977690259 cites W2168631000 @default.
• W2977690259 cites W2188278098 @default.
• W2977690259 cites W2192486833 @default.
• W2977690259 cites W2368001341 @default.
• W2977690259 cites W2527905628 @default.
• W2977690259 cites W2557730509 @default.
• W2977690259 cites W2560367415 @default.
• W2977690259 cites W2588270164 @default.
• W2977690259 cites W2590359520 @default.
• W2977690259 cites W2591628935 @default.
• W2977690259 cites W2595109242 @default.
• W2977690259 cites W2622595542 @default.
• W2977690259 cites W2734670400 @default.
• W2977690259 cites W2737044461 @default.
• W2977690259 cites W2742802588 @default.
• W2977690259 cites W2760825739 @default.
• W2977690259 cites W2766564423 @default.
• W2977690259 cites W2766903152 @default.
• W2977690259 cites W2774712455 @default.
• W2977690259 cites W2782333299 @default.
• W2977690259 cites W2782949806 @default.
• W2977690259 cites W2784538417 @default.
• W2977690259 cites W2784548224 @default.
• W2977690259 cites W2785869969 @default.
• W2977690259 cites W2789550512 @default.
• W2977690259 cites W2791290180 @default.
• W2977690259 cites W2791673886 @default.
• W2977690259 cites W2792241534 @default.
• W2977690259 cites W2797675588 @default.
• W2977690259 cites W2804812017 @default.
• W2977690259 cites W2804957255 @default.
• W2977690259 cites W2805354595 @default.
• W2977690259 cites W2883858361 @default.
• W2977690259 cites W2883867140 @default.
• W2977690259 cites W2884754721 @default.
• W2977690259 cites W2886963239 @default.
• W2977690259 cites W2887169335 @default.
• W2977690259 cites W2887449433 @default.
• W2977690259 cites W2888572922 @default.
• W2977690259 cites W2889218664 @default.
• W2977690259 cites W2889555301 @default.
• W2977690259 cites W2892640821 @default.
• W2977690259 cites W2896372714 @default.
• W2977690259 cites W2897230620 @default.
• W2977690259 cites W2898706486 @default.
• W2977690259 cites W2914335731 @default.
• W2977690259 cites W2916508569 @default.
• W2977690259 cites W2917696006 @default.
• W2977690259 cites W2920290633 @default.
• W2977690259 cites W2938994710 @default.
• W2977690259 cites W2943984025 @default.
• W2977690259 cites W2947248753 @default.
• W2977690259 cites W2947612917 @default.
• W2977690259 cites W2951934596 @default.
• W2977690259 cites W2965234655 @default.
• W2977690259 cites W2981716146 @default.
• W2977690259 cites W2982786601 @default.
• W2977690259 cites W4210992155 @default.
• W2977690259 cites W4235182817 @default.
• W2977690259 cites W4242460399 @default.
• W2977690259 cites W4242648511 @default.
• W2977690259 cites W4253193856 @default.
• W2977690259 cites W585853313 @default.
• W2977690259 doi "https://doi.org/10.3390/ijms20194931" @default.
• W2977690259 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6801651" @default.

• next